2256
vs
H
Hang Seng (Hong Kong)
2256
Over the past 12 months, Abbisko Cayman Ltd has significantly outperformed Hang Seng (Hong Kong), delivering a return of +98% compared to the Hang Seng (Hong Kong)'s +16% growth.
Stocks Performance
2256 vs Hang Seng (Hong Kong)
Performance Gap
2256 vs Hang Seng (Hong Kong)
Performance By Year
2256 vs Hang Seng (Hong Kong)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Abbisko Cayman Ltd
Glance View
Abbisko Cayman Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of drugs and small molecule oncology therapies. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-10-13. The firm is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The firm owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company’s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).
